Table II.
Clinical characteristics of the validation cohort, and association with BRAF V600E status in tumors.
| BRAF V600E in tumors | ||||
|---|---|---|---|---|
| Clinical characteristic | No. patients | Positive (n=26) | Negative (n=33) | P-value |
| Age (median, range) | 41 (22–65) | 39 (22–64) | 41 (22–65) | 0.283 |
| Sex | ||||
| Male (%) | 17 (28.81%) | 7 | 10 | 0.078 |
| Female (%) | 42 (71.19%) | 19 | 23 | |
| Tumor size, cm; median (range) | 1.8 (0.2–5.4) | 1.7 (0.2–4.6) | 2.3 (0.6–5.4) | 0.658 |
| LNM | ||||
| Positive (%) | 20 (33.90) | 15 | 5 | 0.001b |
| Negative (%) | 39 (66.10) | 11 | 28 | |
| Capsule invasion | ||||
| Positive (%) | 20 (33.90) | 11 | 9 | 0.226 |
| Negative (%) | 39 (66.10) | 15 | 24 | |
| Stage | ||||
| I+II (%) | 38 (64.41) | 12 | 26 | 0.009a |
| III+IV (%) | 21 (35.59) | 14 | 7 | |
a
P<0.01
b
P<0.001. LNM, lymph node metastasis.